Novo Nordisk (NVO) announced on Monday that it has filed a lawsuit against Hims & Hers (HIMS), accusing the telehealth platform of violating its rights to a key U.S. patent related to its weight loss therapy, semaglutide.
The Danish drugmaker
Novo files patent suit against Hims & Hers over Wegovy knockoffs
